Mohan Sobhana Nandhu

Mohan Sobhana Nandhu

Auto-generated profile, based on publicly available information

Mohan Sobhana Nandhu

Brigham and Women's Hospital, Harvard Medical School, 4 Blackfan Circle, Boston, Massachusetts 02115, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2013 in Cancers
Verified
Journal Article
Open access
PDF file
AKAneta Kwiatkowska
Aneta Kwiatkowska
MNMohan S. Nandhu
Mohan S. Nandhu
PBPrajna Behera
Prajna Behera
ACAntonio Chiocca
Antonio Chiocca
MVMariano S Viapiano
Mariano S Viapiano
Glioblastoma (GBM) is the most aggressive form of brain cancer, with a dismal prognosis and extremely low percentage of survivors. Novel therapies are in dire need to improve the clinical management of these tumors and extend patient survival. Genetic therapies for GBM have been postulated and attempted for the past twenty years, with variable degrees of success in pre-clinical models and clinical trials. Here we review the most common approaches to treat GBM by gene therapy, including strategies to deliver tumor-suppressor genes, suicide genes, immunomodulatory cytokines to improve immune response, and conditionally-replicating oncolytic viruses. The review focuses on the strategies used for gene delivery, including the most common and widely used vehicles (i.e., replicating and non-replicating viruses) as well as novel therapeutic approaches such as stem cell-mediated therapy and nanotechnologies used for gene delivery. We present an overview of these strategies, their targets, different advantages, and challenges for success. Finally, we discuss the potential of gene therapy-based strategies to effectively attack such a complex genetic target as GBM, alone or in combination with conventional therapy.

31 July 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
BHBin Hu
Bin Hu
MNMohan S. Nandhu
Mohan S. Nandhu
HSHosung Sim
Hosung Sim
PAPaula A. Agudelo-Garcia
Paula A. Agudelo-Garcia
JSJoshua C. C Saldivar
Joshua C. C Saldivar
MVMariano S Viapiano
Mariano S Viapiano
Malignant gliomas are highly invasive and chemoresistant brain tumors with extremely poor prognosis. Targeting of the soluble factors that trigger invasion and resistance, therefore, could have a significant impact against the infiltrative glioma cells that are a major source of recurrence. Fibulin-3 is a matrix protein that is absent in normal brain but upregulated in gliomas and promotes tumor invasion by unknown mechanisms. Here, we show that fibulin-3 is a novel soluble activator of Notch signaling that antagonizes DLL3, an autocrine inhibitor or Notch, and promotes tumor cell survival and invasion in a Notch-dependent manner. Using a strategy for inducible knockdown, we found that controlled downregulation of fibulin-3 reduced Notch signaling and led to increased apoptosis, reduced self-renewal of glioblastoma-initiating cells, and impaired growth and dispersion of intracranial tumors. In addition, fibulin-3 expression correlated with expression levels of Notch-dependent genes and was a marker of Notch activation in patient-derived glioma samples. These findings underscore a major role for the tumor extracellular matrix in regulating glioma invasion and resistance to apoptosis via activation of the key Notch pathway. More importantly, this work describes a noncanonical, soluble activator of Notch in a cancer model and shows how Notch signaling can be reduced by targeting tumor-specific accessible molecules in the tumor microenvironment. Cancer Res; 72(15); 3873–85. ©2012 AACR.

1 July 2010 in Fitoterapia
Verified
Journal Article
Closed access
JMJobin Mathew
Jobin Mathew
JPJes Paul
Jes Paul
MNM.S. Nandhu
M.S. Nandhu
CPC.S. Paulose
C.S. Paulose

24 May 2016 in Biomedical Optics Express
Verified
Journal Article
Open access
PDF file
YZYanyu Zhao
Yanyu Zhao
STSyeda Tabassum
Syeda Tabassum
SPShaheer Piracha
Shaheer Piracha
MNMohan Sobhana Nandhu
Mohan Sobhana Nandhu
MVMariano Viapiano
Mariano Viapiano
DRDarren Roblyer
Darren Roblyer
Spatial frequency domain imaging (SFDI) is a widefield imaging technique that allows for the quantitative extraction of tissue optical properties. SFDI is currently being explored for small animal tumor imaging, but severe imaging artifacts occur for highly curved surfaces (e.g. the tumor edge). We propose a modified Lambertian angle correction, adapted from the Minnaert correction method for satellite imagery, to account for tissue surface angles up to 75°. The method was tested in a hemisphere phantom study as well as a small animal tumor model. The proposed method reduced µa and µs` extraction errors by an average of 64% and 16% respectively compared to performing no angle correction, and provided more physiologically agreeable optical property and chromophore values on tumors.

30 September 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MNMohan S. Nandhu
Mohan S. Nandhu
BHBin Hu
Bin Hu
SCSusan E. Cole
Susan E. Cole
AEAnat Erdreich-Epstein
Anat Erdreich-Epstein
DRDiego J. Rodriguez-Gil
Diego J. Rodriguez-Gil
MVMariano S Viapiano
Mariano S Viapiano
High-grade gliomas are characterized by exuberant vascularization, diffuse invasion, and significant chemoresistance, resulting in a recurrent phenotype that makes them impossible to eradicate in the long term. Targeting protumoral signals in the glioma microenvironment could have significant impact against tumor cells and the supporting niche that facilitates their growth. Fibulin-3 is a protein secreted by glioma cells, but absent in normal brain, that promotes tumor invasion and survival. We show here that fibulin-3 is a paracrine activator of Notch signaling in endothelial cells and promotes glioma angiogenesis. Fibulin-3 overexpression increased tumor VEGF levels, microvascular density, and vessel permeability, whereas fibulin-3 knockdown reduced vessel density in xenograft models of glioma. Fibulin-3 localization in human glioblastomas showed dense fiber-like condensations around tumor blood vessels, which were absent in normal brain, suggesting a remarkable association of this protein with tumor endothelium. At the cellular level, fibulin-3 enhanced endothelial cell motility and association to glioma cells, reduced endothelial cell sprouting, and increased formation of endothelial tubules in a VEGF-independent and Notch-dependent manner. Fibulin-3 increased ADAM10/17 activity in endothelial cells by inhibiting the metalloprotease inhibitor TIMP3; this resulted in increased Notch cleavage and increased expression of DLL4 independently of VEGF signaling. Inhibition of ADAM10/17 or knockdown of DLL4 reduced the proangiogenic effects of fibulin-3 in culture. Taken together, these results reveal a novel, proangiogenic role of fibulin-3 in gliomas, highlighting the relevance of this protein as an important molecular target in the tumor microenvironment. Cancer Res; 74(19); 5435–48. ©2014 AACR.

1 October 2009 in Epilepsy & Behavior
Verified
Journal Article
Closed access
AKAmee Krishnakumar
Amee Krishnakumar
MNM.S. Nandhu
M.S. Nandhu
CPC.S. Paulose
C.S. Paulose